Shankar Musunuri, Ocugen CEO
Manufacturing problems trigger another clinical hold for troubled Covid-19 vaccine — latest in a string of roadblocks
Just days after the World Health Organization suspended the use of Covaxin after a manufacturing site failed an inspection, the FDA has followed up with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.